

Important Information on Coronavirus (COVID-19) and the Use of CIMZIA® (certolizumab pegol)

We appreciate your concern for your patients and the complexity of providing care in the context of the COVID-19 (coronavirus) pandemic. At this time, in the absence of data to inform the use of biologics in this setting, we are unable to provide guidance regarding continuation or discontinuation of CIMZIA (certolizumab pegol) in otherwise healthy patients. We recognize that the risks and benefits of continued treatment in this setting are specific to the individual patient. In accordance with the [CIMZIA prescribing information](#), CIMZIA should not be initiated in patients with an active infection. Patients should be monitored for infection during and after treatment, and CIMZIA should be discontinued if a serious infection develops.

While there are no specific guidelines for patients treated with immunomodulatory or immunosuppressive medications, the Centers for Disease Control and Prevention have published guidance for individuals at higher risk. This information can be found at: <https://www.cdc.gov/coronavirus/2019-ncov/specific-groups/high-risk-complications.html>. We encourage you to follow closely the changing recommendations of the CDC and local regulatory authorities during this health crisis.